Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

The Company announced a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo. Under the agreement, Syndax received $350 million in exchange for a 13.8% ...

Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...

Protagonist Therapeutics is a late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are in advanced Phase 3 clinical ...

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago. These ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Tens of thousands of U.S. citizens live in the Israeli-occupied territory, on opposing sides of an entrenched conflict, where neither Palestinians nor Israelis have much enthusiasm for Kamala ...